WO2000041505A3 - Anthranilic acid derivatives - Google Patents

Anthranilic acid derivatives Download PDF

Info

Publication number
WO2000041505A3
WO2000041505A3 PCT/US1999/030491 US9930491W WO0041505A3 WO 2000041505 A3 WO2000041505 A3 WO 2000041505A3 US 9930491 W US9930491 W US 9930491W WO 0041505 A3 WO0041505 A3 WO 0041505A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid derivatives
anthranilic acid
compound
formula
treating
Prior art date
Application number
PCT/US1999/030491
Other languages
French (fr)
Other versions
WO2000041505A2 (en
Inventor
Haile Tecle
Stephen Douglas Barrett
Original Assignee
Warner Lambert Co
Haile Tecle
Stephen Douglas Barrett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Haile Tecle, Stephen Douglas Barrett filed Critical Warner Lambert Co
Priority to BR9916857-0A priority Critical patent/BR9916857A/en
Priority to CA002349180A priority patent/CA2349180A1/en
Priority to EP99968160A priority patent/EP1150950A2/en
Priority to AU24834/00A priority patent/AU2483400A/en
Priority to JP2000593128A priority patent/JP2002534446A/en
Publication of WO2000041505A2 publication Critical patent/WO2000041505A2/en
Publication of WO2000041505A3 publication Critical patent/WO2000041505A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C07C323/35—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group
    • C07C323/36—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group the sulfur atom of the sulfide group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

The invention features a compound having the formula (I) below. The invention also relates to a pharmaceutical composition including (a) a compound of formula (I) and (b) a pharmaceutically-acceptable carrier. The invention further relates to a method for treating proliferative diseases such as cancer, restenosis, psoriasis, autoimmune disease, and atherosclerosis. Other aspects of the invention include methods for treating MEK-related (including ras-related) cancers, whether solid or hematopoietic.
PCT/US1999/030491 1999-01-13 1999-12-21 Anthranilic acid derivatives WO2000041505A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BR9916857-0A BR9916857A (en) 1999-01-13 1999-12-21 4 heteroaryl diarylamines
CA002349180A CA2349180A1 (en) 1999-01-13 1999-12-21 Anthranilic acid derivatives
EP99968160A EP1150950A2 (en) 1999-01-13 1999-12-21 Anthranilic acid derivatives
AU24834/00A AU2483400A (en) 1999-01-13 1999-12-21 4'heteroaryl diarylamines
JP2000593128A JP2002534446A (en) 1999-01-13 1999-12-21 4'heteroaryldiarylamine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11587699P 1999-01-13 1999-01-13
US60/115,876 1999-01-13
US12258399P 1999-03-02 1999-03-02
US60/122,583 1999-03-02

Publications (2)

Publication Number Publication Date
WO2000041505A2 WO2000041505A2 (en) 2000-07-20
WO2000041505A3 true WO2000041505A3 (en) 2000-10-19

Family

ID=26813668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030491 WO2000041505A2 (en) 1999-01-13 1999-12-21 Anthranilic acid derivatives

Country Status (6)

Country Link
EP (1) EP1150950A2 (en)
JP (1) JP2002534446A (en)
AU (1) AU2483400A (en)
BR (1) BR9916857A (en)
CA (1) CA2349180A1 (en)
WO (1) WO2000041505A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE250932T1 (en) * 1999-07-16 2003-10-15 Warner Lambert Co METHOD FOR TREATING CHRONIC PAIN BY ADMINISTRATION OF A MEK INHIBITOR
DOP2003000556A (en) 2002-01-23 2003-10-31 Warner Lambert Co ESTERES HYDROXAMATE ACID N- (4-PHENYL-REPLACED) -ANTRANILICO.
MXPA04005527A (en) 2002-01-23 2005-03-23 Warner Lambert Co N-(4-substituted phenyl)-anthranilic acid hydroxamate esters.
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
EP1682495A1 (en) 2003-10-21 2006-07-26 Warner-Lambert Company LLC Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101223914B1 (en) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Akt protein kinase inhibitors
UA89035C2 (en) * 2003-12-03 2009-12-25 Лео Фарма А/С Hydroxamic acid esters and pharmaceutical use thereof
US7956191B2 (en) 2004-10-20 2011-06-07 Merck Serono Sa 3-arylamino pyridine derivatives
TWI441637B (en) 2005-05-18 2014-06-21 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EA019983B1 (en) * 2005-10-07 2014-07-30 Экселиксис, Инк. Mek inhibitors and methods of using same
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
JPWO2007132867A1 (en) 2006-05-15 2009-09-24 杉本　芳一 Preventive and therapeutic agents for cancer
MY147628A (en) 2006-07-06 2012-12-31 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
DE602007011628D1 (en) 2006-07-06 2011-02-10 Array Biopharma Inc DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2007353385A1 (en) 2006-10-23 2008-11-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
CA2671982C (en) 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
CN103396409B (en) 2007-07-05 2015-03-11 阵列生物制药公司 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2692506C (en) 2007-07-05 2015-11-24 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8022057B2 (en) 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
CA2711699A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2240455B1 (en) 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
BRPI0916566B8 (en) 2008-08-04 2021-05-25 Merck Patent Ges Mit Beschraenkter Haftung Phenylamine isonicotinamide, its use, pharmaceutical composition, and kit
ES2399384T3 (en) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido substituted phenoxybenzamides
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
EP2491014A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
ES2526675T3 (en) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonylbenzamides as voltage dependent sodium channel inhibitors
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
CN103841976A (en) 2011-04-01 2014-06-04 基因泰克公司 Combinations of AKT AND MEK inhibitor compounds, and methods of use
US9833439B2 (en) 2011-05-25 2017-12-05 Universite Paris Descartes ERK inhibitors for use in treating spinal muscular atrophy
CN103204822B (en) 2012-01-17 2014-12-03 上海科州药物研发有限公司 Benzoxazole compounds as protein kinase inhibitors, and preparation method and application thereof
EP2826474B1 (en) * 2012-03-14 2021-05-26 Sinochem Corporation Use of substituted diphenylamine compounds in preparing anti-tumour drugs
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. Novel process for making compounds for use in the treatment of cancer
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
CA2923835C (en) * 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (en) 2015-03-31 2018-02-06 Massachusetts Gen Hospital SELF-ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY
CN108524482B (en) * 2017-03-02 2022-11-25 中国科学院上海药物研究所 Use of 2- (substituted phenylamino) benzoic acid FTO inhibitors for treating leukemia
CN114907267A (en) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 Pharmaceutical composition for resisting tumor
TW202342018A (en) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Inhibitors of mek kinase

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2082171A (en) * 1933-05-24 1937-06-01 Winthrop Chem Co Inc Basically substituted amino acridine derivatives
US2502451A (en) * 1945-05-07 1950-04-04 Ward Blenkinsop & Co Ltd Amino-alkyl esters of diphenylamine 2-monocarboxylic acids
US2553914A (en) * 1948-03-22 1951-05-22 Ward Blenkinsop & Co Ltd Substituted diphenylamine 2-monocarboxylic acids and the production thereof
DE2155106A1 (en) * 1970-11-06 1972-05-10 Ciba-Geigy Ag, Basel (Schweiz) New nitrodiphenylamines, their manufacture and use
US3781358A (en) * 1968-05-29 1973-12-25 E Anderson Intermediates for preparing acridines
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
EP0242559A2 (en) * 1986-03-15 1987-10-28 Hoechst Aktiengesellschaft Use of amino-substituted benzoic acids as remedies for diarrhoea, and medicaments on the basis of these compounds
EP0316630A1 (en) * 1987-10-27 1989-05-24 Warner-Lambert Company Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
WO1999021840A1 (en) * 1997-10-28 1999-05-06 Warner-Lambert Company Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2082171A (en) * 1933-05-24 1937-06-01 Winthrop Chem Co Inc Basically substituted amino acridine derivatives
US2502451A (en) * 1945-05-07 1950-04-04 Ward Blenkinsop & Co Ltd Amino-alkyl esters of diphenylamine 2-monocarboxylic acids
US2553914A (en) * 1948-03-22 1951-05-22 Ward Blenkinsop & Co Ltd Substituted diphenylamine 2-monocarboxylic acids and the production thereof
US3781358A (en) * 1968-05-29 1973-12-25 E Anderson Intermediates for preparing acridines
DE2155106A1 (en) * 1970-11-06 1972-05-10 Ciba-Geigy Ag, Basel (Schweiz) New nitrodiphenylamines, their manufacture and use
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
EP0242559A2 (en) * 1986-03-15 1987-10-28 Hoechst Aktiengesellschaft Use of amino-substituted benzoic acids as remedies for diarrhoea, and medicaments on the basis of these compounds
EP0316630A1 (en) * 1987-10-27 1989-05-24 Warner-Lambert Company Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
WO1999021840A1 (en) * 1997-10-28 1999-05-06 Warner-Lambert Company Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
A.H. COOK ET AL, J. CHEM. SOC., 1943, pages 417 - 419 *
CHEMICAL ABSTRACTS, vol. 35, no. 22, 20 November 1941, Columbus, Ohio, US; abstract no. 7965h, XP002142607 *
CHEMICAL ABSTRACTS, vol. 38, no. 1, 10 January 1944, Columbus, Ohio, US; abstract no. 105, XP002142608 *
CHEMICAL ABSTRACTS, vol. 59, no. 8, 14 October 1963, Columbus, Ohio, US; abstract no. 8753f, XP002142606 *
CHEMICAL ABSTRACTS, vol. 70, no. 3, 20 January 1969, Columbus, Ohio, US; abstract no. 11330, XP002142605 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142609 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142610 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142611 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142612 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142614 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142615 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002142616 *
DATABASE CROSSFIRE BEILSTEIN INSTITUT FUER LITERATUR DER ORGANISCHEN CHEMIE; XP002142613 *
E.S. ENDELMAN ET AL, KHIM.-FARM. ZH., vol. 7, no. 12, 1973, pages 15 - 19 *
F. HUNZIKER ET AL, ARZNEIMITTEL-FORSCH., vol. 13, 1963, pages 324 - 328 *
M. TAKEDA ET AL, YAKUGAKU ZASSHI, vol. 89, no. 2, 1969, pages 158 - 163 *
N.A. MOKHORT, FARMAKOL. TOKSIKOL. (KIEV), no. 6, 1971, pages 108 - 111 *
V.O. YU ET AL, J. GEN. CHEM. USSR, vol. 11, 1941, pages 243 - 253 *

Also Published As

Publication number Publication date
BR9916857A (en) 2001-12-04
CA2349180A1 (en) 2000-07-20
JP2002534446A (en) 2002-10-15
EP1150950A2 (en) 2001-11-07
AU2483400A (en) 2000-08-01
WO2000041505A2 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
WO2000041505A3 (en) Anthranilic acid derivatives
NZ337861A (en) N-heterocyclic derivatives for treating multiple sclerosis, HIV dementia, Parkinson's disease, meningitis, atherosclerosis, cancer, inflammatory skin diseases
BG103417A (en) Condensed pyrimidine bicyclic derivatives
WO1999054326A8 (en) Dihydropyrimidines
GR3030342T3 (en) Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase.
PL346797A1 (en) Arylsulfonanilide ureas
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO1998051294A3 (en) Method and composition for treating cancers
HK1021699A1 (en) Pentafluorobenzenesulfonamides and analogs.
IL156967A0 (en) Camptothecin derivatives
DE69907419D1 (en) Antitumorwirkstoffe
WO2004084812A3 (en) Tamandarin analogs and fragments thereof and methods of making and using
CA2429133A1 (en) Novel imidazole derivatives, production method thereof and use thereof
AU6369900A (en) Aromatic esters of camptothecins and methods to treat cancers
DE60214359D1 (en) Stickstoffbasierte camptothecin-derivate
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
EP1109560A4 (en) Compounds useful as aicarft inhibitors
AU2003300385A1 (en) Anticancer compounds
MY104829A (en) 3-phenyl-5, 6-dihydrobenz [c]acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents.
DE69911017D1 (en) Arylsulfonanilid-phosphate
YU19302A (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
WO1996025400A3 (en) 3-aromatic and 3-heteroaromatic substituted bisnaphthalimides
AU3412600A (en) Peroxovanadium compounds as antineoplastic agents for the treatment of cancer
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2349180

Country of ref document: CA

Ref country code: CA

Ref document number: 2349180

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004851

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999968160

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09889106

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 593128

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999968160

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999968160

Country of ref document: EP